Literature DB >> 6418723

Haloperidol: a quarter century of experience.

E C Settle, F J Ayd.   

Abstract

Research on haloperidol's pharmacokinetics, side effects, indications, and efficacy is reviewed. Issues related to high-dose therapy, rapid neuroleptization, intravenous administration, use in geriatric patients, and coadministration with lithium in mania are discussed. Overall, 25 years of experience have indicated that haloperidol can be used safely and effectively to manage a variety of psychiatric illnesses, so long as dosage and method of administration are adjusted to individual patients' needs. Research continues on the use of this drug, not only in psychiatry but in several other areas of medical practice.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6418723

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  9 in total

Review 1.  Haloperidol dosing strategies in the treatment of delirium in the critically ill.

Authors:  Erica H Z Wang; Vincent H Mabasa; Gabriel W Loh; Mary H H Ensom
Journal:  Neurocrit Care       Date:  2012-02       Impact factor: 3.210

Review 2.  Delirium.

Authors:  D Taylor; S Lewis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-07       Impact factor: 10.154

3.  Enantioselective Synthesis of Oxetanes Bearing All-Carbon Quaternary Stereocenters via Iridium-Catalyzed C-C Bond-Forming Transfer Hydrogenation.

Authors:  Yi-An Guo; Wonchul Lee; Michael J Krische
Journal:  Chemistry       Date:  2017-01-27       Impact factor: 5.236

4.  Implementation of a delirium assessment tool in the ICU can influence haloperidol use.

Authors:  Mark van den Boogaard; Peter Pickkers; Hans van der Hoeven; Gabriel Roodbol; Theo van Achterberg; Lisette Schoonhoven
Journal:  Crit Care       Date:  2009-08-10       Impact factor: 9.097

5.  Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.

Authors:  Timothy D Girard; Matthew C Exline; Shannon S Carson; Catherine L Hough; Peter Rock; Michelle N Gong; Ivor S Douglas; Atul Malhotra; Robert L Owens; Daniel J Feinstein; Babar Khan; Margaret A Pisani; Robert C Hyzy; Gregory A Schmidt; William D Schweickert; R Duncan Hite; David L Bowton; Andrew L Masica; Jennifer L Thompson; Rameela Chandrasekhar; Brenda T Pun; Cayce Strength; Leanne M Boehm; James C Jackson; Pratik P Pandharipande; Nathan E Brummel; Christopher G Hughes; Mayur B Patel; Joanna L Stollings; Gordon R Bernard; Robert S Dittus; E Wesley Ely
Journal:  N Engl J Med       Date:  2018-10-22       Impact factor: 91.245

6.  Agitation in the ICU: part one Anatomical and physiologic basis for the agitated state.

Authors: 
Journal:  Crit Care       Date:  1999       Impact factor: 9.097

7.  Use of neuroleptics in a general hospital.

Authors:  Raquel Barba; Javier Garay; Helena Martín-Alvarez; Carlos Herrainz; Virgilio Castellanos; Isabel Gonzalez-Anglada; Angel Puras
Journal:  BMC Geriatr       Date:  2002-05-03       Impact factor: 3.921

8.  Gene-microRNA interactions associated with antipsychotic mechanisms and the metabolic side effects of olanzapine.

Authors:  Danielle M Santarelli; Bing Liu; Carlotta E Duncan; Natalie J Beveridge; Paul A Tooney; Peter R Schofield; Murray J Cairns
Journal:  Psychopharmacology (Berl)       Date:  2013-01-15       Impact factor: 4.530

9.  Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation.

Authors:  Mohd Yasir; Udai Vir Singh Sara
Journal:  Acta Pharm Sin B       Date:  2014-11-21       Impact factor: 11.413

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.